RMC Switchgears has received an order worth Rs 90 crore for 5,000 solar pumps in Maharashtra, an exchange filing said.
Analysts have ‘buy’ calls on Glenmark Pharmaceuticals Ltd., Hyundai Motor India Ltd., GE Vernova T&D India Ltd., Schneider Electric Infrastructure Ltd. and Prestige Estates Projects Ltd. The stock calls came from Shrikant Chouhan, executive vice president and head equity research, Kotak Securities Ltd., Milan Vaishnav, CMT, MSTA, founder and technical analyst, Gemstone Equity Research and Sneha S
Read here.
India's food delivery aggregator Zomato Ltd. is set to bring in an inflow of $513 million or approximately Rs 4,356 crore, as it gears up to replace JSW Steel Ltd. in the upcoming December Sensex rejig, according to Nuvama Alternative & Quantitative Research.
Read more here.
Piramal Pharma share price rose nearly 5% on Tuesday after JM Financial initiated coverage on the stock with a 'buy' rating, and a target price of Rs 340, implying a 36% potential upside.
The stock is currently trading at a 38% discount to its listed peers, making it an attractive opportunity for investors, holds the brokerage.
At pre-open, Nifty 50 was at 24584.80, down 0.34% or 83.45 points and Sensex was at 81514.75, down by 0.29% or 233.82 points.
The yield on the 10-year bond opened flat at 6.74%.
It closed at 6.74% on Monday.
Source: Bloomberg
Rupee weakened by 3 paise to a record low of 84.9 against the US Dollar. It closed at 84.87 on Monday.
Source: Bloomberg
Citi has maintained 'buy' with a target price of Rs 485, implying downside of 5.6%. Board Announces 4th Interim Dividend of Rs 8.5/share, record date 24th December.
Carraro India has set price band at Rs 668-704/share and bid for issue will open on December 20 and close on December 24, a company statement said.
JM Financial has initiated coverage on Piramal Pharma with a buy rating and a target of Rs 340, implying 36% upside. India’s CRDMO market is expected to double by 2028, boosting opportunities and Piramal Pharma’s global capabilities position it to capitalize on growth. CDMO segment is expected to grow at 17% CAGR over 3 years and recovery in US biotech from 2HFY25 will support growth. The company's overall revenue projected to grow at 15% CAGR over FY24-27 and margins to expand by 360 bps to 18%.
Most markets in Asia–Pacific markets were trading higher ahead of the Federal Reserve policy outcome. South Korea's Kospi traded in red as political uncertainties in the nation continue to weigh on investors' sentiments.
On Monday, the Dow Jones Industrial Average ended 0.25% down. The S&P 500 and Nasdaq Composite ended 0.38% and 1.24% higher, respectively.
Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit.